Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | M6PR | P20645 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14817881 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL12262915 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL5982317 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL12205501 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL23867729 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL13509339 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL23522673 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL4921744 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL23549931 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR | |
| SCHEMBL22030605 | 1.00 | THRB (0.38) | THRBLMNAMEN1KMT2ATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626460-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | The University of Queensland (AU) | 2025-10-08 | — | — | EP | disclosed |
| US-20250275993-A1 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-04 | — | — | US | disclosed |
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| CN-113135966-B | Bicyclic derivatives of heterocyclic glucoside and preparation method and application thereof | 华润双鹤药业股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20210188890-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-06-24 | — | — | US | disclosed |
| US-20210121383-A1 | COMPOSITION FOR ANTI-AGING | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3156058-B1 | ANTI-TUMOR PHARMACEUTICAL APPLICATION OF PENTACYCLIC TRITERPENE SAPONIN COMPOUNDS OF SZECHUAN MELANDIUM ROOT | WANG XUEYONG (CN) | 2020-05-27 | — | — | EP | disclosed |
| US-10570164-B2 | Steviol glycosides, their compositions and their purification | THE COCA-COLA COMPANY (US) | 2020-02-25 | — | — | US | disclosed |
| CN-106083943-B | Glucopyranosyl derivative and preparation method and application thereof | 广东东阳光药业有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3140314-B1 | A NON-CALORIC SWEETENER | CONAGEN INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-12-09 | — | — | US | disclosed |
| US-7846945-B2 | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100028559-A1 | Method for functionalizing materials and devices comprising such materials | THE STATE OF OREGON ACTING BY AND THROUGH STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND | 2010-02-04 | — | — | US | disclosed |
| US-20090098172-A1 | SURFACTANT, AND EMULSION COSMETIC AND LIPOSOME EACH CONTAINING THE SAME | KAO CORPORATION (JP) | 2009-04-16 | — | — | US | disclosed |
| WO-2008156510-A2 | METHOD FOR FUNCTIONALIZING MATERIALS AND DEVICES COMPRISING SUCH MATERIALS | STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
| WO-2007141513-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
| EP-1730159-B1 | DERIVATIVES OF GENKWANIN AND SAKURANETIN, COSMETIC AND THERAPEUTIC USE THEREOF AND PREPARATION METHOD OF SAME | PROST MICHEL (FR) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | SLC2A1, SLC2A2, SLC5A2 | THRB 815/4885LMNA 3320/4885MEN1 4606/4885 |
| US-20100028559-A1 | Method for functionalizing materials and devices comprising such materials | ALDH1A2, LGALS3, LGALS3BP | THRB 4158/4885LMNA 879/4885MEN1 3122/4885 |
| US-20210121383-A1 | COMPOSITION FOR ANTI-AGING | GLA, GLB1, LIMS1 | THRB 3995/4885LMNA 613/4885MEN1 4528/4885 |
| US-10570164-B2 | Steviol glycosides, their compositions and their purification | TAS2R7, TAS2R31, TAS2R40 | THRB 3858/4885LMNA 4183/4885MEN1 1223/4885 |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | GPR119, FABP4, LIPC | THRB 477/4885LMNA 3376/4885MEN1 4167/4885 |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | SLC2A1, SLC2A2, SLC5A2 | THRB 815/4885LMNA 3320/4885MEN1 4606/4885 |
| US-20090098172-A1 | SURFACTANT, AND EMULSION COSMETIC AND LIPOSOME EACH CONTAINING THE SAME | TREH, LIPA, SGMS1 | THRB 2803/4885LMNA 2591/4885MEN1 3332/4885 |
| US-20210188890-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | GALE, FBP1, GNE | THRB 2056/4885LMNA 4488/4885MEN1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.